996 resultados para Philadelphia
Resumo:
Includes bibliographical references
Resumo:
Vols. 11-20 compiled by Henry C. Brown.
Resumo:
Binding: brown goatskin, tooled in blind and with seal of the United States Centennial Commission in gilt centered on each board. Edges of boards and turn-ins tooled in gilt. Page edges gilt.
Resumo:
Latest issue consulted: 1936/1937.
Resumo:
Latest issue consulted: 9th (1920).
Resumo:
Supplements accompany some issues.
Resumo:
Mode of access: Internet.
Resumo:
Mode of access: Internet.
Resumo:
Preface signed: E. A. B. [i.e. Edwin Atlee Barber]
Resumo:
"The manuscript of this work is in the library of the American philosophical society. It is a copy made by Mr. Duponceau, and forms no. xxvii of a collection made by him and recorded in a folio account book, of which it occupies pp. 114-119."--Pilling, Bibl. of the Algonquin languages, p. 227.
Resumo:
Microfilmed for preservation
Resumo:
The present thesis encompasses the two researches projects I conducted during my PhD program in Molecular Biology and Pathology. The common thread is represented by the analysis of the signaling pathways implicated in the pathophysiology of the two most aggressive Philadelphia-negative myeloproliferative neoplasms, namely, atypical chronic myeloid leukemia (aCML) and primary myelofibrosis (PMF). In the last decade, since the description of the JAK2V617F mutation in 2005, the field of the molecular characterization of Philadelphia-negative myeloproliferative neoplasms has experienced an astonishing implementation that led to the discovery of 16 new mutations involving signal transduction, epigenetic modifiers, cell cycle regulators. Nevertheless, their pathogenetic relevance and whether they could represent good druggable candidates have to be proved yet. In the first section I provide the first report of the signaling cascade down-stream the rare cytogenetic lesion t(8;9)(p22;p24)/PCM1-JAK2 associated with aCML, finding that it selectively activates the ERK1/2 signaling without affecting JAK/STAT phosphorylation. In the second part, I investigated the implication of the isoform of novel Protein kinase Cs (PKCs) in the pathophysiology of the aberrant megakaryocytopoiesis in PMF, concluding that the over-expression of PKC detains a crucial relevance in the aberrant behavior of PMF megakaryocytes and its inhibition is capable to restore their normal differentiation and abrogate the anti-apoptotic signaling. Both results are discussed in the view of their therapeutic implications. In case PCM1/JAK2-related hematologic neoplasms, ERK-inhibitors rather than JAK-inhibitors (i.e. ruxolitinib) should be considered as a tailored drugs. In case of PMF, PKC-inhibitors (i.e. V1-2 peptide) configure as an appealing strategy to re-direct the megakaryocytic neoplastic clone.
Resumo:
General note: Title and date provided by Bettye Lane.